Zadaxin thymalfasin: Additional pilot trial data

Additional data from an ongoing, open-label, Italian pilot trial in 120 patients with ESRD on hemodialysis showed that Focetria influenza vaccine plus 3.2 or 6.4 mg Zadaxin significantly increased the proportion of patients with seroconversion at 42 days post-vaccination vs. Focetria alone (93% and 94% vs. 77%; p=0.04 for both). Patients received Focetria plus 3.2 or 6.4 mg Zadaxin given 7 days prior to vaccination and on the day of vaccination or Focetria alone. Additional data will be reported at 184 days post-vaccination. Last month, the partners reported that Zadaxin met the primary endpoint of a significantly greater proportion of patients achieving seroconversion at 21 days post-vaccination vs. Focetria alone (see BioCentury, Jan. 18). ...